Immunological Aspects of Approved MS Therapeutics

Multiple sclerosis (MS) is the most common neurological immune-mediated disease leading to disability in young adults. The outcome of the disease is unpredictable, and over time, neurological disabilities accumulate. Interferon beta-1b was the first drug to be approved in the 1990s for relapsing-rem...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Front Immunol
Main Authors: Rommer, Paulus S., Milo, Ron, Han, May H., Satyanarayan, Sammita, Sellner, Johann, Hauer, Larissa, Illes, Zsolt, Warnke, Clemens, Laurent, Sarah, Weber, Martin S., Zhang, Yinan, Stuve, Olaf
Formato: Artigo
Idioma:Inglês
Publicado: Frontiers Media S.A. 2019
Assuntos:
Immunology
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC6637731/
https://ncbi.nlm.nih.gov/pubmed/31354720
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fimmu.2019.01564
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares